%3Aformat(webp)&w=3840&q=75)
Xintela: Awaiting final follow-up data
Research update Q2 2025
|2025-09-05
- The 24-month follow-up data to be reported by the end of Q3
- The GMP production facility is generating revenue
- Adjusted for dilution, our fair value amounts to SEK 1.28 per share
Xintela’s half-year report did not reveal any surprises. As announced in Q1, XSTEM in knee osteoarthritis (OA) has been proven safe and tolerable by the 18-month data in all three dose levels. In Q2, the last patient in the phase I/IIa study was followed up. The complete 24-month data from the highest dose level is expected to be reported by the end of September. Our model suggests a fair value of SEK 1.28 per share.
%3Aformat(webp)&w=3840&q=75)
Martin Dominique
Chief analyst
%3Aformat(webp)&w=3840&q=75)
Tobias Karlsson
Analyst